Skip to main content
GenFleet Therapeutics (Shanghai) Inc. logo

GenFleet Therapeutics (Shanghai) Inc. — Investor Relations & Filings

Ticker · 2595 HKEX Manufacturing
Open in API
Filings indexed 667 across all filing types
Latest filing 2025-10-21 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2595

About GenFleet Therapeutics (Shanghai) Inc.

http://www.genfleet.com

GenFleet Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies in oncology and immunology. Established in 2017, the company employs a "Global New" strategy centered on source innovation, targeting novel biological pathways and indications that have not yet achieved clinical validation to build a differentiated, high-value pipeline. GenFleet has demonstrated particular expertise in developing RAS-pathway targeted therapies. The company integrates international clinical and commercial development routes, utilizing global strategic cooperation to facilitate the future entry of its products into worldwide markets.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Exchange ‘FF305 Next Day Disclosure Return’ detailing a change in issued shares (issue and allotment of H shares via over-allotment). This is a disclosure of new share issuance, matching the definition for Share Issue/Capital Change (SHA).
2025-10-21 English
VOLUNTARY ANNOUNCEMENT EFFICACY DATA OF GFH375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, FOR PANCREATIC DUCTAL ADENOCARCINOMA PATIENTS PRESENTED AS A LATE-BREAKING ABSTRACT IN AN ORAL PRESENTATION A
Regulatory Filings Classification · 1% confidence The document is a voluntary regulatory announcement on the Hong Kong Exchange summarizing clinical trial efficacy data presented at an academic conference. It is not an annual or interim financial report, not an earnings release, not a dividend or capital notice, and not any of the other highly specific categories. It provides business/clinical updates and forward-looking statements, fitting the general “Regulatory Filings” fallback category for miscellaneous announcements (RNS).
2025-10-20 English
FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement regarding the full exercise of the over-allotment option in the company’s Global Offering, detailing the issuance and allotment of additional H Shares, the resulting shareholding structure, use of proceeds, and public float. This constitutes an announcement of new share issuance/capital change, fitting the “Share Issue/Capital Change” category (SHA).
2025-10-16 English
Notification Letter to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 1% confidence The document is a formal notice to non-registered shareholders regarding the electronic dissemination arrangement of all future corporate communications under Hong Kong Listing Rule 2.07. It does not itself present financial results, an annual report, proxy materials for voting, nor a specific report publication but rather explains how corporate communications will be delivered and includes an opt-in reply form. This routine regulatory announcement does not fit any of the specific categories (e.g., 10-K, ER, PSI, DIV, etc.) and serves as a miscellaneous Listing Rule filing, making “Regulatory Filings (RNS)” the appropriate classification.
2025-10-15 English
Notification Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 1% confidence The document is a shareholder notification regarding the adoption of electronic dissemination of corporate communications under HKEX Listing Rule 2.07. It is not an actual financial report (e.g., annual or interim report), proxy solicitation, dividend notice, or other specific filing category. It serves as a general regulatory announcement to shareholders about a change in communications method. Therefore, it falls into the fallback category of Regulatory Filings (RNS).
2025-10-15 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2025
Capital/Financing Update Classification · 1% confidence The document is a standard FF301 monthly return filed with the Hong Kong Stock Exchange under Listing Rule Chapter 19B, detailing movements in authorised, registered, and issued share capital for the month ended 30 September 2025. This is a routine update of the company’s capital structure rather than an earnings report, management commentary, or proxy materials. It serves as a capital/financing update on share capital movements, fitting the definition for “Capital/Financing Update (CAP)”.
2025-10-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.